Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14838MR)

This product GTTS-WQ14838MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14838MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11545MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ12801MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ918MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ12562MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ15704MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ14246MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ5186MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ14905MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW